MAPT and Cognitive impairment: Although [18F]PI-2620 is shown to be an effective tracer in imaging 3R/4R tau in AD and distinguishing these patients from mild cognitive impairment (MCI) patients and controls [84], more work is needed to lend similar support to its utility in APs.